PPCB Propanc Biopharma, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1517681 · Fiscal year ends 06/30
Financial factors as of 2026-09-30 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY64.3%
TTM EPS YoY115.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-211.0%
ROA-159.8%
ROIC (approx.)-168.8%
Asset turnover—
Leverage & solvency
Liabilities / assets31.5%
Debt / equity0.00x
Current ratio2.47x
Interest coverage-154.29x
Cash quality & payout
Operating cash flow / net income0.25x
Accruals ratio-119.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 | FY20242024-06-30 | FY20232023-06-30 | FY20222022-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $625,477 | $223,721 | $248,102 | $247,919 | $256,052 |
| SG&A expense | $670,607 | $108,950 | $1.25M | $1.50M | $1.71M |
| Operating income | -$18.19M | -$57.28M | -$1.54M | -$1.78M | -$1.99M |
| Interest expense | $430,539 | $563,757 | $665,841 | $532,821 | $568,798 |
| Pretax income | -$18.86M | -$58.92M | -$1.95M | -$2.79M | -$2.71M |
| Income tax | — | — | -$129,132 | -$129,841 | -$54,977 |
| Net income | -$18.86M | -$58.92M | -$1.82M | -$2.66M | -$2.66M |
| EBITDA | -$18.18M | — | -$1.54M | -$1.77M | -$1.99M |
| EPS (basic) | -17.62 | -371.22 | -1,420.53 | -1.80 | -49.23 |
| EPS (diluted) | -17.62 | -371.22 | -1,420.53 | -1.80 | -49.23 |
| Weighted avg. shares (diluted) | 1.12M | 158,727 | 1,417 | 1.74M | 68,219 |
| Balance sheet | |||||
| Cash & equivalents | $832,006 | $12,088 | $21,085 | $10,047 | $4,067 |
| Current assets | $8.54M | $8.35M | $25,441 | $19,039 | $15,030 |
| PP&E, net | $3,915 | — | — | $302 | $2,023 |
| Total assets | $12.78M | $19.63M | $72,365 | $60,328 | $81,651 |
| Current liabilities | $3.35M | $5.58M | $3.79M | $3.16M | $3.06M |
| Long-term debt | — | $537,921 | $399,325 | $390,539 | $926,438 |
| Total debt | — | $537,921 | $399,325 | $390,539 | $926,438 |
| Total liabilities | $3.38M | $5.73M | $3.85M | $3.18M | $3.11M |
| Shareholders' equity | $9.40M | $13.91M | -$3.78M | -$3.12M | -$3.02M |
| Net debt | — | $525,833 | $378,240 | $380,492 | $922,371 |
| Shares outstanding | 331,083 | 464,471 | 7,980 | 6.03M | 220,351 |
| Cash flow statement | |||||
| Operating cash flow | -$5.68M | -$405,168 | -$935,118 | -$1.11M | -$1.44M |
| Capital expenditure | $4,933 | — | — | — | — |
| Free cash flow | -$5.69M | — | — | — | — |
| Investing cash flow | -$4,933 | — | — | — | — |
| Financing cash flow | $6.46M | $490,756 | $941,894 | $1.11M | $1.49M |
| Depreciation & amortization | $997 | — | $297 | $1,665 | $1,993 |
| Stock-based compensation | $8.50M | $4.62M | — | $2,408 | $72,513 |
Free plan shows the latest 5 periods; Pro shows all 18 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.